



BRIAN SANDOVAL  
Governor

STATE OF NEVADA  
DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
1100 E. William Street, Suite 101  
Carson City, Nevada 89701  
(775) 684-3676 • Fax (775) 687-3893

RICHARD WHITLEY, MS  
Director

MARTA JENSEN  
Acting Administrator

**NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE**

**AGENDA**

**Date of Posting:** Monday, October 26, 2015

**Date of Meeting:** Thursday, December 3, 2015 at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP), Pharmacy and Therapeutics Committee

**Place of Meeting:** JW Marriott – Las Vegas  
Marbella Room  
221 N. Rampart Blvd  
Las Vegas, NV 89145  
Phone: (702) 869-7777  
Please check with hotel staff to verify room location

A visual and audio feed will also be broadcast via the internet and phone for those who are unable to attend in person. See below for details.

**Webinar Pre-Registration:** **\*\*Must Pre-Register\*\***  
<https://catamaranrx.webex.com/catamaranrx/onstage/g.php?MTID=e6caebf863da965b41ca7ba5f5a4c5731>

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

**Webinar Event:** <https://catamaranrx.webex.com/catamaranrx/onstage/g.php?MTID=e6caebf863da965b41ca7ba5f5a4c5731>

**Event Number:** 740 124 858

Click "Join Now"

**Follow the instructions that appear on your screen to join the teleconference.**

**Teleconference: 1 (855) 210-1642**

**Access Code: 3844816**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Robyn Heddy at (775) 684-3678 or email [Robyn.Heddy@dncfp.nv.gov](mailto:Robyn.Heddy@dncfp.nv.gov) in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

**Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.**

## **AGENDA**

**1. Call to Order and Roll Call**

**2. Public Comment**

No action may be taken on a matter raised under this item of the agenda until the matter itself has been specifically included on the agenda as an item upon which action can be taken.

**3. Administrative**

A. **For Possible Action:** Review and Approve Meeting Minutes from September 23, 2015.

B. Status Update by DHCFP

1. Public Comment

**4. Annual Review – Drug Classes Without Proposed Changes From September 23, 2015 Meeting**

A. Public Comment

B. Presentation of Recommendations for Preferred Drug List (PDL) inclusion by OptumRx and the Division of Health Care Financing and Policy without Changes.

C. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

1. Tramadol And Related Drugs
2. Non-Sedating H1 Blockers
3. Inhaled Aminoglycosides
4. Antivirals - Alpha Interferons
5. Anti-Hepatitis Agents – Polymerase Inhibitors/Combination Products
6. Anti-Hepatitis Agents – Protease Inhibitors
7. Anti-Hepatitis Agents – Ribavirins
8. Anti-Herpetic Agents
9. Influenza Agents
10. Second-Generation Cephalosporins
11. Third-Generation Cephalosporins
12. Macrolides
13. Quinolones - 2nd Generation
14. Quinolones - 3rd Generation
15. Self-Injectable Epinephrine
16. Multiple Sclerosis Agents - Specific Symptomatic Treatment
17. Angiotensin II Receptor Antagonists
18. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
19. Calcium-Channel Blockers
20. Direct Renin Inhibitors
21. Vasodilators – Inhaled
22. Bile Acid Sequestrants
23. Cholesterol Absorption Inhibitors
24. Fibric Acid Derivatives
25. Hmg-Coa Reductase Inhibitors (Statins)
26. Niacin Agents
27. Antipsoriatic Agents - Topical Vitamin D Analogs
28. Topical Analgesics
29. Acne Agents: Topical, Benzoyl Peroxide, Antibiotics And Combination Products
30. Impetigo Agents: Topical
31. Topical Antivirals
32. Topical Scabicides
33. Immunomodulators: Topical
34. Topical Retinoids
35. Serotonin-Receptor Antagonists/Combo
36. H2 Blockers
37. Proton Pump Inhibitors (PPIs)

38. Gastrointestinal Anti-inflammatory Agents
39. Gastrointestinal Enzymes
40. 5-Alpha Reductase Inhibitors
41. Alpha-Blockers
42. Bladder Antispasmodics
43. Anticoagulants – Injectable
44. Colony Stimulating Factors
45. Platelet Inhibitors
46. Alpha-Glucosidase Inhibitors/Amylin Analogs/Misc.
47. Biguanides
48. Dipeptidyl Peptidase-4 Inhibitors
49. Meglitinides
50. Sulfonylureas
51. Thiazolidinediones
52. Growth Hormone Modifiers
53. Progestins For Cachexia
54. Antigout Agents
55. Bisphosphonates
56. Nasal Calcitonins
57. Restless Leg Syndrome Agents
58. Skeletal Muscle Relaxants
59. Alzheimer's Agents
60. Barbiturates
61. Benzodiazepines
62. Hydantoins
63. Non-Ergot Dopamine Agonists
64. Carbonic Anhydrase Inhibitors/Beta-Blockers
65. Ophthalmic Prostaglandins
66. Ophthalmic Antihistamines
67. Ophthalmic Macrolides
68. Ophthalmic Quinolones
69. Ophthalmic Corticosteroids
70. Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
71. Otic Quinolones
72. Antidepressants – Other
73. Selective Serotonin Reuptake Inhibitors (SSRIS)
74. Atypical Antipsychotics
75. Nasal Antihistamines
76. Leukotriene Receptor Antagonists
77. Nasal Corticosteroids

78. Phosphodiesterase Type 4 Inhibitors
79. Respiratory Antimuscarinics
80. Long-Acting Respiratory Beta-Agonist
81. Short-Acting Respiratory Beta-Agonist
82. Respiratory Corticosteroid/Long-Acting Beta-Agonist Combinations
83. Antidotes - Opiate Antagonists

## 5. Established Drug Classes

### A. Antidepressants - Other

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action:** Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

### B. Nasal Antihistamines

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action:** Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

### C. Nasal Calcitonins

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action:** Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL.

- D. Platelet Inhibitors
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  
- E. Bladder Antispasmodics
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  
- F. Angiotensin II Receptor Antagonists
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  
- G. Immunomodulators: Topical
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
5. **For Possible Action**: Committee Discussion and Approval of Drugs for Inclusion on the PDL

H. Ophthalmic Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action**: Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
5. **For Possible Action**: Committee Discussion and Approval of Drugs for Inclusion on the PDL

I. Disease-Modifying Antirheumatic Agents

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action**: Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
5. **For Possible Action**: Committee Discussion and Approval of Drugs for Inclusion on the PDL

**6. Established Drug Classes Being Reviewed Due to the Release of New Drugs**

A. Alzheimer's Agents

1. Public Comment
2. Drug Class Review Presentation – OptumRx
3. **For Possible Action**: Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
5. **For Possible Action**: Committee Discussion and Approval of Drugs for Inclusion on the PDL

- B. Oral Atypical Antipsychotics
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  
- C. Ophthalmic Antihistamines
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  
- D. Short-Acting Respiratory Beta-Agonist
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  
- 7. **Report by OptumRx on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions**
  
- 8. **Closing Discussion**
  - A. Public comments on any subject.
  - B. Date and location of the next meeting.



1. Discussion of the time of the next meeting.
- C. Adjournment.

---

This notice and agenda have been posted at <http://dhcfp.nv.gov/> and <http://notice.nv.gov/>.

Notice of this meeting will be available on or after the date of this notice at the DHCFP Web site <http://dhcfp.nv.gov/>, Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to Robyn Heddy at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least 3 days before the public hearing.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.